Multiple Sclerosis Society of Canada

Latest MS Research News

Stay Updated

Subscribe to the latest MS research news by email by entering your info below:


View RSS Feed
   Please leave this field empty

Landmark MS Scientific Research Foundation funded study demonstrates that “rebooting” the immune system stops new disease and leads to recovery in people with aggressive multiple sclerosis

  • Canadian Study
  • MS Society Funded

Background Currently, disease-modifying therapies (DMTs) approved for multiple sclerosis (MS) appear to work by blunting the destructive autoimmune response that targets tissues in the central nervous system (CNS). For many individuals living with MS, DMTs offer measurable therapeutic benefits by suppressing... Read More

Researchers mine MS Scientific Research Foundation-funded biobank to discover a genetic mutation associated with an aggressive form of primary progressive MS

  • Canadian Study
  • MS Society Funded

REVISION: June 3, 2016 Background The precise factors that cause multiple sclerosis continue to puzzle researchers today, although the prevailing view is that a combination of genetic, biological, and environmental factors interacts to trigger the emergence of the disease. Over the past three decades, Read More

MS Society-funded study shows that nicotine reduces the invasion of harmful immune cells into the brain in mice with an MS-like disease

  • Canadian Study
  • MS Society Funded

Background A substantial body of evidence suggests that smoking tobacco increases the risk of developing multiple sclerosis (MS) and may even accelerate disease progression. On the other hand, nicotine, the ingredient in tobacco responsible for its addictive properties, has been shown to have anti-inflammatory... Read More

Early stage study shows that vitamin D can promote myelin repair

Background Vitamin D is an essential nutrient that provides many health benefits, and a great deal of evidence has recognized vitamin D as a protective factor against the development of multiple sclerosis. In addition to its protective effects, vitamin D has recently been put in the spotlight to uncover... Read More

New collaborative study funded by the MS Scientific Research Foundation will explore how the microbes in the gut influence MS in children and adolescents

  • Canadian Study
  • MS Society Funded

Background The lush bacterial ecosystem in our intestines – referred to as the gut microbiome – has co-evolved with humans to give us the means to efficiently break down food and supply us with extracted energy and nutrients. Beyond its role in digestion, the gut microbiome has a profound impact on... Read More

MS Scientific Research Foundation funded multi-site study makes breakthrough in identifying type of white blood cell involved in MS

  • Canadian Study
  • MS Society Funded

Background Research into understanding and treating multiple sclerosis (MS) has largely been centered on a type of white blood cell known as the  T cell or T lymphocyte. T cells are in charge of protecting the body against harmful infections, but in the case of MS T cells have been identified as important... Read More

Researchers link continued smoking to accelerated MS progression

Background There is mounting evidence to suggest that smoking tobacco not only increases a person’s risk of developing multiple sclerosis (MS), but can also accelerate the disorder’s progression. While a number of studies have examined the link between smoking and MS, certain aspects of the relationship... Read More

Sophisticated genetics analysis reveals low vitamin D increases MS risk

Background The majority of studies which attempt to understand if and how environmental exposures such as low vitamin D contribute to the cause of multiple sclerosis are plagued by confounding factors or reverse causation. Confounding means that MS may not actually be caused or linked to vitamin D deficiency, Read More

MS Scientific Research Foundation funded study boosts efforts in pediatric MS research, implications for understanding adult-onset MS

  • Canadian Study
  • MS Society Funded

Background  Before the launch of the Canadian Pediatric Demyelinating Disease Network in 2004, pediatric multiple sclerosis was under-recognized and poorly understood. The prevalence and impact of MS in children and adolescents was unknown, and how their MS differs from MS in adults was yet to be determined. Read More

Two drugs used to treat non-MS conditions promote myelin repair in mice

Background Multiple sclerosis (MS) is a disorder of the  central nervous system (CNS) in which  myelin – the coating that surrounds nerve fibers and is produced by  oligodendrocytes – is attacked and damaged by the immune system. Myelin repair (or  remyelination ) is carried out by a group of cells... Read More

MS Society-funded fellow demonstrates the ability of the hormone prolactin, when combined with interferon-β, to reduce disease severity in animals with MS-like disease.

  • Canadian Study
  • MS Society Funded

Background While we know that women living with multiple sclerosis (MS) often experience fewer relapses during mid to late pregnancy or while breastfeeding, we are not sure why this occurs. One possibility lies with the hormone prolactin. Necessary for milk production, prolactin is at its highest levels... Read More

MS Society-funded fellow publishes study that examines new class of compounds with the potential to protect against nerve damage and halt MS progression

  • Canadian Study

Background One of defining characteristics of multiple sclerosis, particularly in the  progressive phase, is the extensive damage that occurs to axons, or nerve fibres, that are found underneath the  myelin sheath in the  central nervous system . This axonal damage is part of a process called neurodegeneration, Read More

MS Society-funded study puts to test a promising new target for MS treatment that has significant potential to stop neurodegeneration and promote recovery

  • Canadian Study
  • MS Society Funded

Background Standard medications that are available to treat MS work by  influencing the activity of the immune system . The development of these medications is based on the observation that MS is predominantly driven by an autoimmune response, in which the body’s natural defenses start to attack healthy... Read More

Case of PML reported in patient treated with Gilenya®

Updated April 8, 2015 Pharmaceutical company Novartis has reported a case of PML (progressive multifocal leukoencephalopathy) in an individual who had received Gilenya® * (fingolimod) for more than 4 years for the treatment of relapsing-remitting multiple sclerosis (RRMS). Novartis has informed the... Read More

3-year update shows sustained remission following high-dose immunosuppressive therapy and hematopoietic cell transplantation in people with active relapsing-remitting MS

Background Although a variety of disease-modifying therapies (DMTs) are available to treat the damaging inflammation that affects people with relapsing-remitting MS (RRMS), DMTs are only partially effective and two-thirds of people with MS are reported to experience breakthrough disease activity despite... Read More

Looking back on 2014

This year marked some exciting developments in multiple sclerosis research, with every breakthrough bringing us closer to understanding the causes underlying MS and finding ways of improving the quality of life for people affected by MS. The MS Society of Canada has led the charge on fighting MS by... Read More

Emerging myelin-repair drug passes phase 1 safety tests

Background As it stands, multiple sclerosis (MS) drug therapies have traditionally focused on reducing damage to myelin and axons. This takes the shape of therapeutics directed at modifying the disease course. Often they work by interfering with the inflammatory component of MS, resulting in less relapses... Read More

Canadian researchers explore recent evidence on depression in people with MS

  • Canadian Study
  • MS Society Funded

Background Depression – a condition marked by persistently low mood and a loss of interest or pleasure in daily activities – is common among people living with MS, adding significant burden to their well-being. It is challenging to detect depression in individuals with MS, as a distinction must be made... Read More

MS Society supported study reveals neuroprotective role of immune cell

  • MS Society Funded

Background: Microglia are a type of immune cell that act as the primary form of defense in the central nervous system (CNS). Microglia act by killing viruses, bacteria, or other foreign cells, as well as by assisting with wound healing processes by collecting, or “scavenging,” cellular debris. Recent... Read More

A comprehensive, nationwide MS Society-supported study provides clues about factors that contribute to living a long and healthy life with MS

  • Canadian Study
  • MS Society Funded

Background: People with MS are living longer than in the past, likely attributable to a higher life expectancy in general and increasingly effective treatments for MS. Strategies for reducing disability and improving quality of life in later years have thus become of great interest, underlying the need... Read More

MS Society funded study assesses diagnostic criteria for CCSVI

  • Canadian Study
  • MS Society Funded

Background: In June 2010, the National MS Society (USA) and the MS Society of Canada committed over $2.4 million to support seven new research projects that would gain further insight into the relationship between chronic cerebrospinal venous insufficiency (CCSVI) and MS. One of these studies was led... Read More

Toxin from common foodborne bacteria discovered as potential MS trigger

Summary: Researchers at Weill Cornell Medical College in New York presented new findings on the link between a toxin produced by common foodborne bacteria and multiple sclerosis. Dr. Jennifer Linden, who presented the data on behalf of her Weill Cornell colleagues at the 2014 American Society for Microbiology... Read More

Patterns of MS prevalence and care around the world

Background: The Atlas of MS 2013 was made available to the public during the annual meeting of the European Committee for Treatment and Research in MS (ECTRIMS) held in October of this year. The Atlas is a comprehensive overview of population patterns of MS, as well as the distribution of resources... Read More

New data on CCSVI from Canadian study using ‘gold standard’ technique

Study methods: A research group from the University of British Columbia, Vancouver Coastal Health, and University of Saskatchewan published a study in the U.K. medical journal The Lancet , reporting on the prevalence of chronic cerebrospinal venous insufficiency (CCSVI) in people with MS, their unaffected... Read More

MS Society-funded research aims at helping repair nerves damaged by MS

  • Canadian Study
  • MS Society Funded

Background: What do we know about repair in MS? The majority of therapies for MS specifically target components of the immune system that are believed to cause damage to tissues in the brain and spinal cord. Although these ‘immunomodulatory’ treatments are successful in reducing myelin injury, they... Read More

Results from MS Society of Canada funded study exploring CCSVI and MS in children

  • Canadian Study
  • MS Society Funded

Background: Searching for clues about CCSVI and MS in the younger population Often considered a disease which affects adolescents, multiple sclerosis (MS) has been observed in a small percentage of children. Diagnosed before reaching their teenage years, children with MS experience symptoms of a relapsing-remitting... Read More

Copaxone only three times a week is effective for MS

Background: Copaxone Glatiramer acetate (GA), marketed as Copaxone by pharmaceutical company Teva Pharmaceuticals, is one of the most commonly prescribed drugs to treat relapsing-remitting multiple sclerosis (MS) in Canada. Copaxone has ‘immunomodulatory’ effects, meaning it has the ability to alter... Read More

Case of PML reported in European patient treated with Gilenya

Canadian pharmaceutical company Novartis has been recently informed of a report of PML (progressive multifocal leukoencephalopathy) in an individual in Europe who had received Gilenya* (fingolimod) for the treatment of multiple sclerosis (MS). Novartis is working with the reporting physician to further... Read More

New results from MS Society of Canada funded study exploring CCSVI and MS

  • MS Society Funded

Background: Determining the link between CCSVI and MS Chronic cerebrospinal venous insufficiency (CCSVI) is described as a condition in which the veins in the head and neck are narrowed or blocked (an effect known as stenosis) and therefore unable to efficiently remove blood from the brain and spinal... Read More

MS Society supported study yields new information on "remyelination"

  • Canadian Study
  • MS Society Funded

Background: Remyelination and MS Multiple sclerosis symptoms are the result of damage to myelin, a substance which wraps around and protects the wire-like structures known as axons which are found in the brain, spinal cord and optic nerve. Myelin also serves as an insulator for axons, allowing them... Read More

Reprogramming the immune system in people with MS

Background: What is targeted in MS? MS is classified as an autoimmune disease, which means the body's own immune system recognizes components that are naturally found in the body and attacks them as if they are foreign pathogens. In general, each autoimmune disease involves a different target in the... Read More

Canadian study reveals subgroup of T cells which target oligodendrocytes in MS

  • Canadian Study
  • MS Society Funded

Background: Immune cells and targets It is believed that multiple sclerosis disease is prompted by a series of immunological events. However, the mechanism by which immune cells enter the central nervous system (CNS) and cause tissue damage remains to be defined. A group of lymphocytes known as CD4... Read More

New Studies on the Role of Salt in Autoimmunity

Background: The Role of Dietary Salt in Autoimmune Diseases Autoimmune diseases like MS are defined as inappropriate immune responses to cells and tissues in the body. Much work has been done to identify the types of cells involved in these responses, as well as genetic abnormalities that alter cell... Read More

CCSVI Case-Control Neurosonography Results Announced

  • MS Society Funded

Background: Determining the link between CCSVI and multiple sclerosis Chronic cerebrospinal venous insufficiency (CCSVI) has been a topic of active discussion over recent years. The association between CCSVI and MS, originally reported by Dr. Paolo Zamboni, MD from the University of Ferrara in Italy, Read More

Early Relapses, Onset of Progression, and Late Outcome in MS

Summary A team of researchers from England and Germany investigated the relationship between early relapses (within the first 2 years), secondary progression (SP), and late disability in MS. They suggest that the total number of early relapses in the relapsing-remitting phase does not influence the... Read More

Changes in hospitalization rates and length of stay in people with MS

Summary According to findings from a retrospective observational study conducted in British Columbia, hospital admissions for MS have decreased over the past 20 years, but the length of stay has increased. [Charity Evans, PhD; Elaine Kingwell, PhD; Feng Zhu, MSc; Joel Oger, MD, FRCPC, FAAN; Yinshan... Read More

Results of More Than 1,250 Studies Shared at Global MS Research Meeting

Nearly 7,000 investigators convened in Lyon, France in mid-October to present findings at ECTRIMS (European Committee for Treatment and Research in MS), the world’s largest meeting dedicated to MS research. More than 1250 scientific presentations and display posters covered virtually every aspect of... Read More

‘Month of birth’ effect in MS

Summary Researchers from Queen Mary University of London, UK, analyzed datasets from previously published studies of month of birth and subsequent MS risk. They observed a significant increase of MS risk in people living in northern hemisphere countries who were born in April and a reduction in risk... Read More

Vaccinations and MS

During the fall and winter months, many people with MS have questions regarding the safety and efficacy of vaccinations. The following update is based on the most recent information available regarding vaccinations and MS. Please use this information to speak to your family physician and neurologist... Read More

Ginkgo biloba failed to improve cognitive function in people with MS

Summary Results of a placebo-controlled, 12-week clinical trial conducted by researchers from Louisiana State University, New Orleans showed that Ginkgo biloba failed to improve cognitive function in people with MS. Extract from the Ginkgo biloba tree has been used for a variety of medicinal purposes, Read More

Gilenya * Product Monograph Update

Details On July 12, 2012, Health Canada made revisions to its recommended use of Gilenya among patients with relapsing remitting MS. In order to ensure patient safety Novartis updated the Gilenya label to include revised guidance surrounding first dose monitoring, use in people with certain cardiovascular... Read More

UBC study observes natural improvement in MS-related disability

Summary A UBC research team collected on all MS patients with definite MS registered with an MS clinic in British Columbia between 1980 and 2004 (follow up to 2009) from the British Columbian MS database to examine naturally occurring improvements in disability scores (EDSS). The team observed improvements... Read More

FDA Warning About Risk of Seizures with MS Drug fampridine

Details A warning has been issued by the U.S. Food and Drug Administration (FDA) regarding an increased risk of seizures in individuals with MS, treated with fampridine (Ampyra®), developed by Acorda Therapeutics Inc. Ampyra (or Fampyra as it is known in Canada) was approved by the FDA in January 2010... Read More

Study assesses safety and efficacy of BOTOX® for management of tremor

Summary An Australian research team conducted a double-blind, randomized, cross-over study of botulinum toxin type A to evaluate its safety and efficacy in treating arm tremor in people living with MS. Findings from this study suggest that BOTOX® improved arm tremor and tremor-related disability in... Read More

Cancer risk in MS: Findings from a UBC study

Summary Supported by the MS Society of Canada, the Canadian Institutes of Health Research and the Michael Smith Foundation for Health Research, a research team from UBC conducted a large Canadian retrospective cohort study to compare the incidence of all cancers and specific types of cancers following... Read More

Small study reports benefit of cannabis on MS spasticity

Summary Preliminary findings from a small randomized, placebo-controlled, double blind cross-over trial suggested that smoked cannabis was beneficial in reducing spasticity and pain in people with treatment resistant spasticity compared to placebo. [Jody Corey-Bloom MD PhD, Tanya Wolfson MA, Anthony... Read More

FDA issues safety communication about CCSVI and MS

Details The U.S. Food and Drug Administration (FDA) issued a safety communication about the potential risk of procedures and devices used to treat CCSVI (chronic cerebrospinal venous insufficiency) in people living with MS. The FDA reviews these risks and supports further research to understand more... Read More

FAMPYRA now available for prescription in Canada

Details Biogen Idec Canada announced that FAMPYRA (fampridine sustained release tablets or fampridine SR) is now available for prescription in Canada. Health Canada approved Pr FAMPYRA™ on February 10, 2012 for the symptomatic improvement of walking in adults with multiple sclerosis (MS) with walking... Read More

Biogen Idec applies to FDA for approval of oral BG-12 to treat MS

Details Biogen Idec has submitted a New Drug Application to the U.S. Food and Drug Administration for approval to market oral BG-12 (dimethyl fumarate) for the treatment of MS , based on positive results from several clinical trials involving people with relapsing-remitting MS . BG-12 previously received... Read More

Gilenya (fingolimod) under Health Canada review

Summary Health Canada has announced an ongoing safety review of Gilenya (fingolimod) following the reports of serious adverse events, including 11 deaths internationally. At this time, it is not clear whether the deaths were caused by Gilenya or whether other factors may have played a role. There have... Read More

Health Canada approves Botox® to treat neurogenic bladder

Summary Health Canada approved the use of Botox to treat neurogenic bladder (Neurogenic Detrusor Overactivity) associated with MS and spinal cord injury. Botox is a powerful neurotoxin that temporarily blocks connections between the nerves and muscles, resulting in short-term relaxation of the targeted... Read More

Study shows hydrotherapy may improve MS related pain

Summary Spanish researchers investigated the effectiveness of an Ai-Chi aquatic exercise program against pain and other symptoms in a randomized controlled trial involving 71 people with MS and found that the hydrotherapy program significantly reduced pain levels in people with MS and improved fatigue, Read More

Fingolimod (Gilenya®) Under Review

The European Medicines Agency (EMA) has started a review of the disease modifying therapy fingolimod (Gilenya ® ) . The review was initiated following reports issued on January 20, 2012 that 11 deaths have occurred among people being treated with Gilenya. The EMA review is in addition to the review... Read More

Study Offers Insight on How Epstein-Barr Virus May Play a Role in MS

SUMMARY An international team has identified clues that may help explain how Epstein-Barr virus, which has been linked to multiple sclerosis, may contribute to the brain inflammation experienced by people who have MS. In active brain lesions (spots of disease activity) in people who had MS in their... Read More

Possible Safety Issue Being Investigated with Novartis Pill Gilenya

Our sympathies go out to the family of an American who recently died within 24 hours of receiving a first dose of the oral medication Gilenya® ( fingolimod, Novartis). Novartis has confirmed this event and has reported it to the Health Authority around the world including Health Canada.  Details of... Read More

Researchers reveal a dual-protective role of the Hedgehog pathway

  • Canadian Study
  • MS Society Funded

Summary A research team from the University of Montreal Hospital Research Centre (CRCHUM) provide further understanding of the method by which the blood brain barrier (BBB) works to avert attacks of the immune system on the brain. These findings which have been published in the prestigious journal Science... Read More

Research Team Discovers New Type of Spinal Cord Stem Cell

  • Canadian Study

Summary A research team led by a University of British Columbia and Vancouver Coastal Health scientist has discovered a type of spinal cord cell that could function as a stem cell, with the ability to regenerate portions of the central nervous system in people with spinal cord injuries, multiple sclerosis... Read More

B Cell-Derived IL-15 Enhances CD8 T Cell Cytotoxicity and is Increased in MS

  • Canadian Study
  • MS Society Funded

Summary Researchers at the Centre Hospitalier de l'Universite de Montreal, Hopital Notre-Dame in Montreal investigated the involvement of interleukin-15, a cytokine, on CD8 T cells or 'killer T cells' as it relates to the mechanism of MS. [Raphael Schneider, Alma Nazlie Mohebiany, Igal Ifergan, Diane... Read More

Impaired neurosteroid synthesis in multiple sclerosis

  • Canadian Study
  • MS Society Funded

Summary Researchers at the University of Alberta discovered that the genes responsible for producing neurosteroids, which allow brain cells to communicate and enable cell repair and re-growth, are suppressed in people with MS. Increasing the level of these neurosteroids in the central nervous system... Read More

Teriflunomide: Positive Results Reported Following a Phase III Study

  • Canadian Study

Summary Results from a Phase III study involving a new oral disease-modifying therapy, teriflunomide, an agent that inhibits specific immune cells, was shown to reduce relapse rates, disability progression and MRI evidence of disease activity as compared with placebo.  Further studies are ongoing to... Read More

Government of Canada Funds National Neurological Study

  • Canadian Study

Summary The Government of Canada announced investment of almost $6 million to support 10 studies on neurological conditions including multiple sclerosis, Alzheimer's disease, Parkinson's disease, epilepsy and neuromuscular conditions. The funding is part of the $15 million National Population Health... Read More

Breakthrough in the Search for New Treatments for MS

Summary Researchers at the University of Nottingham have discovered a molecular mechanism that encourages the body to produce its own beta-interferon. Some current disease-modifying treatments for relapsing forms of MS provide beta-interferon by injection. This discovery suggests that there might be... Read More

Poor Bone Health May Start Early in MS

Summary Findings from a small study conducted at Oslo University Hospital, Ulleval, Norway, found that poor bone health, including osteoporosis and low bone density, commonly occurs in the early stages of MS. Findings from this study suggest that preventative measures to maintain good bone health may... Read More

New Study on Cost Effectiveness of MS Therapies

Summary A new study co-funded by the National MS Society (USA), the National Institutes of Health and the University of Rochester examined the cost-effectiveness of therapies to treat MS, and found that the cost for improving the quality of life for people with MS in the U.S. is high. The study found... Read More

Merck Serono will not proceed with FDA approval of oral cladribine

Summary Merck Serono has decided not to pursue approval of its oral therapy cladribine ( Movectro ) for the treatment of relapsing forms of multiple sclerosis. In March 2011, the U.S. Food and Drug Administration requested additional analyses or new studies on cladribine from Merck Serono before they... Read More

The psychosocial and cognitive impact of longstanding benign MS

  • Canadian Study

Summary UBC researchers and UBC MS clinic neurologists compared outcomes in people with benign MS (EDSS 3.0) and found that depression and mental health quality of life differed little between the two groups. However, people with longstanding 'benign' MS (EDSS ≤3 for 25+ years) had less fatigue, better... Read More

Pregnancy outcomes in women with multiple sclerosis

  • Canadian Study

Summary UBC researchers, Dr. Helen Tremlett and Mia van der Kop reported findings from a retrospective cohort study she conducted using data from the British Columbia MS Clinics’ database and the British Columbia Perinatal Database Registry to determine if there was a difference in pregnancy related... Read More

Increased Risk of Multiple Sclerosis Following Occurrence of Shingles

Summary Researchers from Taipei Medical University in Taiwan conducted a nationwide, population-based study to investigate the frequency and risk of MS following the occurrence of herpes zoster, the virus commonly known as chicken pox or shingles. Researchers demonstrated an increased risk of developing... Read More

Avonex® PenTM Autoinjector Approved by Health Canada

Summary Biogen Idec. Canada announced Health Canada’s approval to market a new convenient autoinjector, Avonex Pen, for treatment of people with relapsing forms of multiple sclerosis and those with a single demyelinating event. Avonex Pen is the first single-use; once-a-week, intramuscular autoinjector... Read More

MS Society welcomes new national monitoring system

Ottawa – March 23, 2011 – The Multiple Sclerosis Society of Canada welcomes the federal government’s announcement of a national monitoring system that will capture information to help identify disease patterns and track treatments and long-term outcomes for people living with MS. The system announced... Read More

First Oral Disease-Modifying Therapy Approved in Canada (Gilenya®)

  • Canadian Study

View or print this bulletin in its original format. Summary On March 9, 2011, Health Canada approved Gilenya® (fingolimod) capsules, the first oral disease-modifying therapy developed for relapsing-remitting MS. Gilenya (prounounced Jil-EN-ee-ah) has been approved for use in people who have tried one... Read More

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study.

View or print this bulletin in its original format. Summary Laquinimod, an oral novel immunomodulator, was shown to reduce MRI-measured disease activity in relapsing-remitting MS (RRMS) patients. The objective of this work was to  determine whether the safety and efficacy profile of laquinimod, as shown... Read More

MS Researchers Share Progress at Annual ECTRIMS Conference

View or print this bulletin in its original format. More than 5,500 neurologists and other investigators from around the world convened in Gothenburg, Sweden on October 13-16 to present findings at the annual ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) conference. More... Read More

Pathophysiology of multiple sclerosis and the place of teriflunomide

View or print this bulletin in its original format. Summary Significant progress in multiple sclerosis (MS) treatment has been made over the last two decades, including the emergence of disease-modifying therapy (DMT). However, substantial unmet medical need persists and has stimulated the search for... Read More

MS Society partners in CCSVI clinical trial

  • Canadian Study

September 28, 2012 – Halifax – The Multiple Sclerosis Society of Canada welcomes the federal government’s announcement that the Phase I/II clinical trial for chronic cerebrospinal venous insufficiency (CCSVI) has received the necessary medical and ethical approvals required to proceed. The national... Read More

Calnexin Deficiency Leads to Dysmyelination

  • MS Society Funded

View or print this bulletin in its original format. Summary Edmonton – Researchers have identified a gene that leads to a chain of events which impacts the speed at which messages are relayed in the nervous system. The work involved a team of researchers – throughout Alberta and around the world and... Read More

The natural history of secondary progressive multiple sclerosis

  • Canadian Study

View or print this bulletin in its original format. Summary A study of over 5,000 people with MS , researchers pinpointed motor symptoms at onset (such as muscle stiffness known as spasticity) and male gender as factors associated with a faster progression from relapsing-remitting MS to secondary-progressive... Read More

MS Society of Canada commits $1 million for CCSVI clinical trial

  • Canadian Study
  • MS Society Funded

Toronto, Ontario - September 16, 2010 – The Multiple Sclerosis Society of Canada board of directors unanimously approved a motion to reserve $1 million for a chronic cerebrospinal venous insufficiency (CCSVI) and MS pan-Canadian therapeutic clinical trial. The funding will be set aside so that an immediate... Read More

Emerging effects of comorbidities on multiple sclerosis

  • Canadian Study

View or print this bulletin in its original format. Summary Although the interaction between comorbidities and chronic diseases is strong, the effect of comorbidities receives little attention in many chronic diseases. In multiple sclerosis (MS), an increasing amount of evidence suggests that physical... Read More

Emerging Therapies in Relapsing-Remitting Multiple Sclerosis

  • Canadian Study

James J. Marriott* and Paul W. Q'Connor Reviews on Recent Clinical Trials, 2010, 5, 179-188. View or print this bulletin in its original format. Details Disease modifying therapy (DMT) first became available for relapsing-remitting multiple sclerosis (RRMS) fifteen years ago with the development of... Read More

Natalizumab drug holiday in multiple sclerosis: Poorly Tolerated

View or print this bulletin in its original format. Summary Natalizumab is a new therapy option for people with multiple sclerosis (MS). It has been suggested that natalizumab-associated progressive multifocal leukoencephalopathy may be prevented by structured interruptions of treatment. Although numbers... Read More

The natural history of secondary progressive multiple sclerosis

  • Canadian Study

View or print this bulletin in its original format. Summary The onset of secondary progression is a pivotal event in the course of relapsing-remitting (RR) multiple sclerosis (MS). Patients with secondary progressive MS (SPMS) experience continuous worsening of symptoms independent of the occurrence... Read More

Executive Functioning in Children and Adolescents with Multiple Sclerosis

  • Canadian Study

View or print this bulletin in its original format. Summary Executive Functions (EF) include a range of superordinate abilities that control performance across many tasks allowing for cognitive efficiency and mental flexibility. Although EFs are commonly affected in MS, little is known about the EF... Read More

Nocebo effects in multiple sclerosis trials: a meta-analysis

View or print this bulletin in its original format. Summary Aimed to estimate the incidence and severity of nocebo responses in trials of symptomatic treatments (STs) and disease-modifying treatments (DMTs) for multiple sclerosis (MS). Papadopoulos D, Mitsikostas DD.  Mult Scler. 2010 Jul;16(7):816-28. Read More

Impact on activities of daily living using a functional electrical stimulation device to improve dropped foot in people with multiple sclerosis, measured by the Canadian Occupational Performance Measure

View or print this bulletin in its original format. Summary Dropped foot is a common problem following multiple sclerosis. In a randomised controlled trial, the authors studied 64 people with unilateral dropped foot who were assigned to either a group using a specific electrical stimulator or receiving... Read More

Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients

  • Canadian Study

View or print this bulletin in its original format. Summary FTY720 (Fingolimod) is a new therapy that reduces disease activity by decreasing numbers of a specific immune system cell. The authors investigated patients who discontinued therapy during clinical investigation and they found that the reconstitution... Read More

New perspectives in the natural history of multiple sclerosis

  • Canadian Study

View or print this bulletin in its original format. Summary In this review, researchers from the University of British Columbia highlight recent advances in MS natural history over the last 5 years, with a focus on long-term population-based cohorts and factors associated with disease progression. Tremlett... Read More

Increasing use of disease modifying drugs for MS in Canada

  • Canadian Study

View or print this bulletin in its original format. Summary University of Toronto investigators report on the utilization of disease modifying drugs in Canada. Rotstein DL, Mamdani M, O'Connor PW. Can J Neurol Sci. 2010 May;37(3):383-8. Details The course of multiple sclerosis may be slowed by use of... Read More

Vitamin D and multiple sclerosis

View or print this bulletin in its original format. Summary A role of adequate vitamin D nutrition in the prevention of multiple sclerosis (MS) was originally proposed to explain the geographical distribution of MS, but only recently has the relation between various measures of vitamin D (eg, sun exposure, Read More

Acne medication may delay progress of multiple sclerosis

  • Canadian Study
  • MS Society Funded

Canadian researchers investigate common medication as alternative MS treatment Calgary, October 25, 2007 – A common acne medication that has been available for over 30 years has the potential to delay the progress of multiple sclerosis and if proven effective, will offer an inexpensive option for the... Read More